thalidomide has been researched along with Angiofollicular Lymph Hyperplasia in 22 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 8.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome." | 5.32 | Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004) |
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 4.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal PCD, and at least one of the minor criteria." | 2.61 | POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. ( Dispenzieri, A, 2019) |
| "Castlemans disease is the term for reactive lymphocytary and plasmocytary proliferation which occurs in the unicentric (localized) form, usually without systemic symptoms, or in the generalized/multicentric form, typically with systemic symptoms (www." | 2.53 | [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature]. ( Adam, Z; Čermáková, Z; Hanke, I; Koukalová, R; Král, Z; Krejčí, M; Křen, L; Mayer, J; Michalková, E; Penka, I; Petrášová, H; Pour, L; Pourová, E; Řehák, Z; Sandecká, V; Ševčíková, S; Sokol, F; Szturz, P; Volfová, P, 2016) |
| "POEMS syndrome is a clonal plasma cell disease characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes." | 2.49 | New advances in the diagnosis and treatment of POEMS syndrome. ( Li, J; Zhou, DB, 2013) |
| "Systematic search for monoclonal gammopathy by immunofixation and serum free light chains is very useful for the management of progressive peripheral neuropathies of unknown origin." | 2.47 | [New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome]. ( Adams, D; Bourhis, JH; Lacroix, C; Lozeron, P; Ribrag, V; Theaudin, M, 2011) |
| "Castlemans disease (also called angiofollicular lymph node hyperplasia) can take two forms with different prognosis: the localized form can usually be treated by a surgical intervention and has therefore a favourable prognosis." | 1.39 | [PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview]. ( Adam, Z; Cervinková, I; Hanke, I; Koukalová, R; Král, Z; Krejčí, M; Křen, L; Mayer, J; Penka, I; Pour, L; Rehák, Z; Storková, T; Svoboda, T; Szturz, P, 2013) |
| "Castleman disease is a rare lymphoproliferative disorder." | 1.35 | Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris. ( Gonda, A; Illes, A; Miltenyi, Z; Remenyik, E; Tar, I; Toth, J, 2009) |
| "Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology." | 1.32 | Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. ( Lee, FC; Merchant, SH, 2003) |
| "Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome." | 1.32 | Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Lomas, OC | 1 |
| Streetly, M | 1 |
| Pratt, G | 1 |
| Cavet, J | 1 |
| Royston, D | 1 |
| Schey, S | 2 |
| Ramasamy, K | 2 |
| Zhou, X | 1 |
| Wei, J | 1 |
| Lou, Y | 1 |
| Xu, G | 1 |
| Yang, M | 1 |
| Liu, H | 1 |
| Mao, L | 1 |
| Tong, H | 1 |
| Jin, J | 1 |
| van Rhee, F | 1 |
| Stone, K | 1 |
| Dispenzieri, A | 1 |
| Adam, Z | 4 |
| Szturz, P | 4 |
| Křen, L | 2 |
| Krejčí, M | 4 |
| Pour, L | 4 |
| Svoboda, T | 1 |
| Hanke, I | 2 |
| Penka, I | 2 |
| Koukalová, R | 4 |
| Rehák, Z | 4 |
| Cervinková, I | 1 |
| Storková, T | 1 |
| Král, Z | 3 |
| Mayer, J | 4 |
| Lin, Q | 1 |
| Fang, B | 1 |
| Huang, H | 1 |
| Yu, F | 1 |
| Chai, X | 1 |
| Zhang, Y | 1 |
| Zhou, J | 1 |
| Xia, Q | 1 |
| Li, Y | 1 |
| Song, Y | 1 |
| Michalková, E | 1 |
| Pourová, E | 1 |
| Volfová, P | 1 |
| Sandecká, V | 1 |
| Čermáková, Z | 1 |
| Sokol, F | 1 |
| Petrášová, H | 1 |
| Ševčíková, S | 1 |
| Stary, G | 1 |
| Kohrgruber, N | 1 |
| Herneth, AM | 1 |
| Gaiger, A | 1 |
| Stingl, G | 1 |
| Rieger, A | 1 |
| Miltenyi, Z | 1 |
| Toth, J | 1 |
| Gonda, A | 1 |
| Tar, I | 1 |
| Remenyik, E | 1 |
| Illes, A | 1 |
| Adams, D | 1 |
| Lozeron, P | 1 |
| Theaudin, M | 1 |
| Ribrag, V | 1 |
| Bourhis, JH | 1 |
| Lacroix, C | 1 |
| Zhao, X | 1 |
| Shi, R | 1 |
| Jin, X | 1 |
| Zheng, J | 1 |
| Wang, X | 1 |
| Ye, S | 1 |
| Xiong, C | 1 |
| Gao, J | 1 |
| Xiao, C | 1 |
| Xing, X | 1 |
| Chovancová, J | 1 |
| Stehlíková, O | 1 |
| Klabusay, M | 1 |
| Zahradová, L | 2 |
| Hájek, R | 2 |
| Briani, C | 1 |
| Manara, R | 1 |
| Lessi, F | 1 |
| Citton, V | 1 |
| Zambello, R | 1 |
| Adami, F | 1 |
| Gandhi, S | 1 |
| Tenant-Flowers, M | 1 |
| Ceesay, M | 1 |
| Corderoy, S | 1 |
| Marcus, R | 1 |
| Nebeský, T | 1 |
| Li, J | 1 |
| Zhou, DB | 1 |
| Lee, FC | 2 |
| Merchant, SH | 1 |
| Jung, CP | 1 |
| Emmerich, B | 1 |
| Goebel, FD | 1 |
| Bogner, JR | 1 |
| Menegato, MA | 1 |
| Canelles, MF | 1 |
| Tonutti, E | 1 |
| Pizzolitto, S | 1 |
| Starkey, CR | 1 |
| Joste, NE | 1 |
| Kim, SY | 1 |
| Lee, SA | 1 |
| Ryoo, HM | 1 |
| Lee, KH | 1 |
| Hyun, MS | 1 |
| Bae, SH | 1 |
5 reviews available for thalidomide and Angiofollicular Lymph Hyperplasia
| Article | Year |
|---|---|
POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management.
Topics: Adrenal Cortex Hormones; Allografts; Bortezomib; Castleman Disease; Diagnosis, Differential; Humans; | 2019 |
[Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Castleman Disease; Drug Therapy, Combination; | 2016 |
[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome].
Topics: Amyloid; Amyloid Neuropathies; Biomarkers; Biopsy; Castleman Disease; Combined Modality Therapy; Dru | 2011 |
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Le | 2012 |
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromo | 2013 |
17 other studies available for thalidomide and Angiofollicular Lymph Hyperplasia
| Article | Year |
|---|---|
The management of Castleman disease.
Topics: Adrenal Cortex Hormones; Anti-Retroviral Agents; Antibodies, Monoclonal; Antineoplastic Combined Che | 2021 |
Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.
Topics: Adult; Castleman Disease; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans | 2017 |
Storming the Castle with TCP.
Topics: Castleman Disease; Cyclophosphamide; Humans; Prednisone; Thalidomide; Thyroid Neoplasms | 2019 |
[PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview].
Topics: Castleman Disease; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Huma | 2013 |
Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Castleman Dis | 2015 |
Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Castleman Disease; HIV Infections; H | 2008 |
Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris.
Topics: Adrenal Cortex Hormones; Castleman Disease; Cyclosporine; Female; Humans; Immunomodulation; Immunosu | 2009 |
Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases.
Topics: Adult; Biopsy, Needle; Castleman Disease; Diagnosis, Differential; Drug Therapy, Combination; Female | 2011 |
Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
Topics: Adult; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Castleman Disease; Drug Therapy, Combinat | 2011 |
Lenalidomide: a new treatment option for Castleman disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Humans; Le | 2012 |
Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Topics: Aged; Castleman Disease; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; | 2012 |
Rituximab and thalidomide combination therapy for Castleman disease.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Castleman Disease; Drug Therapy, Combination; Female; | 2012 |
Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide.
Topics: Adult; Anemia; Antibodies, Viral; Axilla; Biopsy; Castleman Disease; Cytokines; Female; Herpesvirus | 2003 |
Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Castleman Disease; HIV Infections; Humans; Immunosuppressive Agents; | 2004 |
Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.
Topics: Aged; Biopsy; Castleman Disease; Female; Glomerulonephritis, Membranoproliferative; Humans; Immunosu | 2004 |
Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide.
Topics: Angiogenesis Inhibitors; Biopsy; Castleman Disease; Female; Humans; Lymph Nodes; Remission Induction | 2006 |
Thalidomide for POEMS syndrome.
Topics: Adult; Anti-Inflammatory Agents; Castleman Disease; Dexamethasone; Female; Humans; Immunosuppressive | 2006 |